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Mesenchymal stem cells (MSCs) are, due to their immunomodulatory characteristics, utilized in therapy of immune-mediated
diseases. We used murine model of cisplatin nephrotoxicity to explore the eﬀects of MSCs on immune cells involved in the
pathogenesis of this disease. Intraperitoneal application of MSCs signiﬁcantly attenuated cisplatin nephrotoxicity, decreased
inﬂammatory cytokines TNF-α and IL-17, and increased anti-inﬂammatory IL-10, IL-6, nitric oxide (NO), and kynurenine in
sera of cisplatin-treated mice. MSC treatment signiﬁcantly attenuated inﬂux of leukocytes, macrophages, dendritic cells (DCs),
neutrophils, CD4+ T helper (Th), and CD8+ cytotoxic T lymphocytes (CTLs) in damaged kidneys and attenuated the capacity
of renal-inﬁltrated DCs, CD4+ Th, and CD8+ CTLs to produce TNF-α and IL-17. Similar eﬀects were observed after
intraperitoneal injection of MSC-conditioned medium (MSC-CM) indicating that MSCs exert their beneﬁcial eﬀects in
paracrine manner. Inhibition of inducible nitric oxide synthase (iNOS) in MSC-CM resulted with increased number of TNF-α-
producing DCs and IL-17-producing CTLs, decreased number of IL-10-producing tolerogenic DCs and regulatory CD4+FoxP3
+ T cells, and completely diminished renoprotective eﬀects of MSC-CM. In conclusion, MSCs, in iNOS-dependent manner,
attenuated inﬂammation in cisplatin nephrotoxicity by reducing the inﬂux and capacity of immune cells, particularly DCs and T
lymphocytes, to produce inﬂammatory cytokines.
1. Introduction
Acute renal injury, characterized by tubular cell damage
and kidney dysfunction, may be developed as a conse-
quence of drug-induced toxicity [1]. As one of the most
eﬀective chemotherapeutics, cisplatin has been used for
the therapy of a broad range of solid tumors including
lung, ovarian, bladder, gastric, and testicular cancers [2].
However, clinical application of cisplatin is limited because
of nephrotoxicity that, as a serious side eﬀect, occurs in
nearly 30% of cisplatin-treated patients [3]. Cisplatin,
which could be metabolized to a potent nephrotoxin-
reactive thiol, selectively accumulates in proximal tubular
cells to ﬁve times higher degree of the serum concentra-
tion and damages proximal tubular epithelial cells, con-
tributing to nephrotoxicity [3]. Acute cisplatin-induced
nephrotoxicity is associated with a robust inﬂammatory
response followed by inﬁltration of immune cells that pro-
motes further progression of renal tissue damage leading
to the development of renal failure [4, 5].
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In many cisplatin-treated patients, kidney injury, man-
ifested by increased serum creatinine and blood urea
nitrogen (BUN) levels and decreased renal blood ﬂow,
hypomagnesemia, hypocalcemia, and proteinuria [3], is
irreversible, requiring substitution, reduction, or discontin-
uation of cisplatin treatment. Since currently there is no
compatible and convenient chemotherapeutic agent with
similar potent, anticancer eﬃcacy as cisplatin, the clinical
use of cisplatin cannot be abandoned. Accordingly, an
urgent demand exists for researchers to develop new adjuvant
therapy for attenuation of cisplatin-induced nephrotoxicity
and inﬂammation.
Mesenchymal stem cells (MSCs) are adult, self-renewable,
multipotent cells which are, due to their diﬀerentiation and
immunomodulatory characteristics, used in preclinical and
clinical studies of degenerative and immune-mediated
diseases [6–8].
Recently, MSC-based therapeutic approach for attenua-
tion of cisplatin-induced nephrotoxicity has been exten-
sively investigated, and several possible mechanisms were
proposed. As demonstrated by Ashour et al. [9], renoprotec-
tive eﬀects of intraperitoneally injected MSCs were based
on MSC-mediated reduction of oxidative stress. Signiﬁ-
cantly decreased renal tissue malondialdehyde, increased
reduced glutathione level, and superoxide dismutase activ-
ity were noticed in cisplatin-treated rats that received
MSCs [9].
Additionally, Kim et al. [10] and Yao et al. [11] demon-
strated that MSCs markedly improved cisplatin-induced
renal failure by suppressing apoptosis in paracrine and
p53-dependent manner. Alleviated kidney injury was
accompanied by decreased expression of cyclooxygenase
COX-2 and tumor necrosis factor alpha (TNF-α), a key
mediator in the inﬂammatory response triggered by cis-
platin, indicating that MSC attenuated cisplatin-induced
nephrotoxicity by modulating kidney inﬂammation. In line
with these ﬁndings, Park et al. [12] recently showed that early
but not late treatment with MSCs attenuates cisplatin-
induced nephrotoxicity and modulates inﬂammation in the
injured kidneys.
Although data presented in these studies [9–12] clearly
demonstrated that MSCs were able to protect the kidney
from the cisplatin-induced toxicity, the eﬀects of MSC on
immune cell-mediated mechanisms involved in induction
and progression of cisplatin-caused kidney inﬂammation
are still unknown. The aim of our study was to investigate
the cellular mechanisms underlying the protective eﬀects of
MSCs on kidney function in order to suggest new pathways
that can be used for the modulation of MSC-dependent
protection of cisplatin-induced nephrotoxicity.
Herewith, we show that single intraperitoneal injection
of MSCs and MSC-conditioned medium (MSC-CM)
diminished inﬂux of immune cells (dendritic cells (DCs),
macrophages, neutrophils, eﬀector CD4+ T helper, and
cytotoxic CD8+ CTL lymphocytes) into the cisplatin-
injured kidneys and attenuated their capacity to produce
nephrotoxic and inﬂammatory cytokines (TNF-α and inter-
leukin- (IL-) 17) in inducible nitric oxide synthase- (iNOS-)
dependent manner.
2. Materials and Methods
2.1. Cells. Mouse bone marrow-derived MSCs were pur-
chased from Gibco (catalog number S1502-100). The cells
were cultured in complete Dulbecco’s Modiﬁed Eagle
Medium (DMEM) containing 10% heat-inactivated fetal
bovine serum (FBS), 100 IU/mL penicillin G, and 100μg/mL
streptomycin (Sigma-Aldrich, Munich, Germany), at 37°C in
a 5%CO2 incubator.MSCs in passage 4 were used throughout
the experiments.
2.2. Generation of MSC-Conditioned Medium (MSC-CM).
MSCs were seeded at a density of 10,000 cells/cm2. In order
to collect the MSC-CM, MSCs were ﬁrst cultured in serum-
containing complete medium and incubated at 37°C in a
humid atmosphere with 5% CO2. At 80% conﬂuence, the
cells were washed twice with 1x phosphate-buﬀered saline
(PBS, Invitrogen), and the medium was then changed to
serum-free medium. After 48 h, the medium was collected,
centrifuged at 13000×g at 4°C for 10min, and stored
at −80°C until used [13].
2.3. Pharmacological Inhibition of iNOS and Indoleamine
2,3-Dioxygenase (IDO). To block iNOS activity, mMSCs
or hMSCs were cultured for 48 h in the presence of 1mM of
an iNOS inhibitor, L-NG-monomethyl arginine citrate
(L-NMMA, Sigma-Aldrich, St. Louis, MO) [14].
MSCs were cultured for 48h in culture medium contain-
ing 1mM 1-methyltryptophan, (1-MT, Sigma-Aldrich, St.
Louis, MO), an inhibitor of IDO enzymatic activity [15].
2.4. In Vitro Activation of MSCs. For in vitro activation,
MSCs were cultured 48 h in the presence of 10 ng/mL recom-
binant mouse TNF-α (Ebioscience, San Diego, USA). IDO
activity in supernatants of TNF-α-activated MSCs was deter-
mined by spectrophotometric measuring of kynurenine
(described under Section 2.11) while expression of iNOS
and IDO was determined by real-time RT-PCR, as described
under Section 2.12.
2.5. Animals. 6–8-week-old male BALB/c mice were ran-
domly divided in control and experimental groups (n = 10
mice/group). All animals received human care, and all exper-
iments were approved by and conducted in accordance with
the Guidelines of the Animal Ethics Committee of the
Faculty of Medical Sciences of the University of Kragujevac,
Serbia. Mice were housed in a temperature-controlled
environment with a 12 hour light-dark cycle and were admin-
istered with standard laboratory chow and water ad libitum.
2.6. Induction of Cisplatin Nephrotoxicity and Application of
MSCs and MSC-CM. Cisplatin nephrotoxicity was induced
by intraperitoneal injection of cisplatin (16mg/kg body
weight) [16]. One hour after the injection of cisplatin,
MSC-treated mice intraperitoneally received 5× 105 MSCs
and resuspended in 200μL of saline, while MSC-CM-
treated mice intraperitoneally received 200μL of MSC-CM.
Mice were randomized to receive cisplatin only, cisplatin
and MSCs, cisplatin and MSC-CM, MSCs, MSC-CM, or
saline only (control mice). After mouse euthanasia (72 h after
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cisplatin treatment), both the kidneys were excised and
blood samples were drawn from the inferior vena cava,
as previously described [16].
2.7. Determination of BUN and Creatinine Levels. Serum
levels of BUN and creatinine were determined to assess the
renal function. After blood collection, serum levels of these
toxicity markers were measured immediately using assay kits
and blood chemistry analyzer, as described [17].
2.8. Histopathological Analysis. The isolated kidneys were
ﬁxed in 10% formalin and embedded in paraﬃn, and consec-
utive 5μm tissue sections were mounted on slides. Sections
were stained with Hematoxylin and Eosin (H&E) and
examined under low-power (100x) light microscopy- (Zeiss
Axioskop 40, Jena, Germany) equipped digital camera.
Histological sections were scored using a semiquantitative
scale designed to assess acute kidney injury-associated
tubular injury (tubular epithelial cell loss, necrosis, tubular
epithelial simpliﬁcation, intratubular debris, and casts) by a
pathologist unaware of the experimental groups (using >5
random ﬁelds/section, 4-5 mice/group). Tubule injury scores
(ranging between 0 and 4) were based on the percentage of
tubules aﬀected as follows: 0≤ 10%, 1=10–25%, 2= 26–
50%, 3=51–75%, and 4≥ 75%, as previously described [18].
Periodic acid-Schiﬀ (PAS) staining was performed on
paraﬃn-embedded kidney tissue sections using PAS Kit
(Sigma-Aldrich, St. Louis, MO) according to the manufac-
turer’s protocol.
2.9. Isolation of Renal-Inﬁltrated Immune Cells. The kidneys
were washed with sterile phosphate-buﬀered saline (PBS)
and placed in Petri dishes with DMEM supplemented with
10% FBS. The kidneys were cut into small pieces (1-2mm
in dimension) using a regular metal shaping blade and placed
into the collagenase solution for 30–45min in the incubator
at 37°C. The cells were ﬁltered through a 70μm nylon cell
strainer into a clean 50mL conical tube. Then, cells were
pelleted by centrifuging 10min at 400×g, at 4°C. Pellet was
resuspended in 4mL of 40% Percoll solution and gently
overlaid onto 4mL of 80% Percoll solution. Slight whitish
translucent layers of cells were collected from the interface
of the two Percoll phases after centrifugation at 1500×g for
30 minutes, at room temperature. These cells were then
collected and pelleted by centrifuging 10min at 400×g, at
4°C. Pellet was resuspended in 1mL of DMEM, and the total
number of cells was determined by using trypan blue
exclusion on a hemocytometer [19].
2.10. Flow Cytometry Analysis and Intracellular Staining of
Renal-Inﬁltrated Immune Cells. Renal-inﬁltrated immune
cells were screened for various cell surface and intracellular
markers with ﬂow cytometry. Brieﬂy, 1× 106 cells were incu-
bated with anti-mouse CD45, F4/80, CD4, CD8, CD11c,
CD11b, Ly6G, and monoclonal antibodies conjugated with
ﬂuorescein isothiocyanate (FITC), phycoerythrin (PE), peri-
dinin chlorophyll protein (PerCP), or allophycocyanin
(APC) (all from BD Biosciences, San Jose, CA, USA) follow-
ing the manufacturer’s instructions. Immune cells derived
from the kidneys were concomitantly stained for the
intracellular content of TNF-α, IL-10, IL-17, and forkhead
box P3 (FoxP3) by using the ﬁxation/permeabilization kit
and anti-mouse monoclonal antibodies conjugated with
ﬂuorescein isothiocyanate (FITC), phycoerythrin (PE), peri-
dinin chlorophyll protein (PerCP), and allophycocyanin
(APC) (BD Bioscience). For intracellular cytokine staining,
cells were stimulated with 50 ng/mL PMA and 500ng/mL
ionomycin for 5 h, and GolgiStop (BD Biosciences) was
added. Cells were ﬁxed in Cytoﬁx/Cytoperm, permeated
with 0.1% saponin, and stained with ﬂuorescent Abs. Flow
cytometric analysis was conducted on a BD Biosciences
FACSCalibur and analyzed by using the Flowing Software
analysis program.
2.11. Measurement of Cytokines and Growth Factors. Levels
of TNF-α, IL-17, IL-10, and IL-6 in the mouse serum were
measured using ELISA kits speciﬁc for the mouse cytokines
(R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions.
Serum concentrations of nitric oxide (NO) were mea-
sured by Griess reagent while IDO activity in serum and
supernatants of TNF-α-stimulated MSCs was determined by
spectrophotometric measuring of kynurenine since IDO cat-
alyzes the metabolism of tryptophan in the kynurenine [20].
2.12. Expression of Genes in Cisplatin-Injured Kidneys and in
TNF-α-Activated MSCs. Total RNA was extracted from fro-
zen mouse kidneys (for determination of IL-6 and TNF-α)
or from cultured MSCs (for determination of NO and
IDO) using TRIzol (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. Total RNA (2μg) was
reverse transcribed to cDNA using High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City,
California, USA). qRT-PCR was performed using Power
SYBR MasterMix (Applied Biosystems) and miRNA-
speciﬁc primers for IL-6, TNF-α, NO, IDO, and β-actin as
a housekeeping gene. qPCR reactions were initiated with a
10-minute incubation time at 95°C followed by 40 cycles of
95°C for 15 seconds and 60°C for 60 seconds in a Mastercy-
cler ep realplex (Eppendorf, Hamburg, Germany). Relative
expression of genes was calculated according to the formula
2 Ct Ctactin , where Ct is the cycle threshold of the gene of
interest and Ctactin is the cycle threshold value of the house-
keeping gene (β-actin) [21].
2.13. Statistical Analysis. The results were analyzed using
Student’s t-test. All data in this study were expressed as the
mean± standard error of the mean (SEM). Values of
p < 0 05 were considered as statistically signiﬁcant.
3. Results
3.1. Intraperitoneal Application of MSCs Signiﬁcantly
Attenuates Cisplatin-Induced Acute Kidney Injury. Cisplatin
caused signiﬁcant renal dysfunction as determined by
biochemical analysis and histological examination.
As shown in Figure 1(a), cisplatin administration
resulted with 4-fold increase in BUN and creatinine when
compared to control mice, indicating the induction of severe
nephrotoxicity. Single, intraperitoneal injection of MSCs did
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Figure 1: MSCs attenuate cisplatin-induced acute kidney injury. (a) Blood urea nitrogen (BUN) and plasma creatinine levels are evaluated.
(b) Histological scores (ranging between 0 and 4) were determinated and calculated on the percentage of tubules aﬀected (0≤ 10%, 1 = 10–
25%, 2 = 26–50%, 3 = 51–75%, and 4≥ 75%). (c) Representative H&E- and PAS-stained mouse kidney. H&E staining images of kidney
tissue samples are shown at the same magniﬁcations (×200). Concentration of (d) cytokines, (e) kynurenine, and (f) NO in mice sera. (g)
IL-6 and TNF-α gene expression in mouse kidneys. Values are mean± SEM; n = 10 mice/group. ∗p < 0 05, ∗∗p < 0 001.
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not alter serum levels of BUN and creatinine in cisplatin-
untreated mice. However, MSCs signiﬁcantly downregulated
serum levels of both BUN (p < 0 05) and creatinine (p < 0 05)
in cisplatin-treated animals suggesting beneﬁcent eﬀects of
MSCs in the treatment of cisplatin-induced nephrotoxicity.
As shown in Figure 1(c), the kidneys obtained from con-
trol and MSC-only treated animals had normal histology.
Partial tubular cell necrosis with citoplasmatic vacuolar
transformation of the tubular epithelium due to hydropic
degeneration and mild interstitial edema with discrete focal
monocyte inﬁltration was noticed in cisplatin-treated mice.
On the contrary, cisplatin +MSC-treated mice showed signif-
icant reduction in renal injury followed by reduced inﬁltra-
tion of inﬂammatory cells (Figure 1(c)). The histological
scores also showed increased tubular injury score after
cisplatin treatment, which was signiﬁcantly reversed by
MSCs (Figure 1(b)).
In accordance with the biochemical and histological
analysis, MSCs did not aﬀect serum levels of cytokines in
cisplatin-untreatedmice indicating that thediﬀerences in their
concentration,betweencisplatin +MSC-treatedandcisplatin-
treated mice (Figure 1(d)), are a consequence of MSC-
mediated suppression of immune cells that produce these
mediators. The concentrations of nephrotoxic and inﬂamma-
tory cytokines TNF-α (p < 0 05) and IL-17 (p < 0 05) were sig-
niﬁcantly lower while concentrations of anti-inﬂammatory
IL-10 (p < 0 01) and IL-6 (p < 0 05) were signiﬁcantly
higher in sera of cisplatin-treated mice that received MSCs
(Figure 1(d)). In line with these ﬁndings, the expression of
TNF-α was signiﬁcantly lower (p < 0 05) while expression
of IL-6 was signiﬁcantly higher (p < 0 05) in the kidneys
of cisplatin +MSC-treated mice when compared to animals
that received only cisplatin (Figure 1(g)). Immunosuppres-
sive kynurenine (p < 0 05, Figure 1(e)) and NO (p < 0 05,
Figure 1(f)) were also elevated in the serum of cisplatin
+MSC-treated mice suggesting that the production of
IDO and NO by MSCs may be important for their benef-
icent eﬀects.
3.2. Inﬂux of Immune Cells and Their Capacity to Produce
Nephrotoxic and Inﬂammatory Cytokines Have Been
Signiﬁcantly Attenuated by MSCs. To assess the role of MSCs
for inﬂammatory cell accumulation in the kidneys after cis-
platin injection, diﬀerent populations of renal-inﬁltrated
immune cells were analyzed by ﬂow cytometry. MSCs did
not alter the total number of renal-inﬁltrated immune cells
in cisplatin-untreated animals. Nevertheless, in cisplatin-
treated mice, inﬂux of immune cells and their capacity to
produce nephrotoxic and inﬂammatory cytokines have been
signiﬁcantly attenuated byMSCs. As shown in Figure 2(a), 72
hours after cisplatin injection, accumulation of CD45+
leukocytes was much less pronounced (p < 0 05) in the
kidneys from cisplatin +MSC-treated mice compared to
cisplatin-only-treated animals.
Cellular make-up of the kidneys (Figure 2(b)) showed
that MSC treatment signiﬁcantly attenuated inﬂux of
CD45+CD11b+ myeloid cells (p < 0 05), CD45+F4/80+
macrophages (p < 0 05), CD45+CD11c+DCs (p < 0 01),
CD45+CD11b+Ly6G+ neutrophils (p < 0 05), CD45+CD4+
helper T cells (p < 0 01), and CD45+CD8+ cytotoxic T cells
(CTLs) (p < 0 01).
Moreover, MSCs attenuate the capacity of DCs, CD4+T
helper, and CD8+ CTLs to produce inﬂammatory cytokines
in cisplatin-injured kidneys. Intracellular staining revealed
signiﬁcantly decreased number of TNF-α-producing DCs
(Figure 2(c), p < 0 05), IFN-γ- and IL-17-producing CD4+
T cells (Figure 2(d), p < 0 01), and IFN-γ- and IL-17-
producing CD8+ CTLs (Figure 2(e), p < 0 01) in the kidneys
of cisplatin-injured mice that received MSCs when compared
to the cisplatin-only-treated animals.
3.3. MSCs Attenuate Cisplatin-Induced Nephrotoxicity in
ParacrineManner.To investigatewhether soluble factorswere
responsible for the MSC-mediated attenuation of cisplatin-
induced nephrotoxicity, cisplatin-treated mice intraperitone-
ally received MSC-CM.
Biochemical analysis showed that MSC-CM did not alter
serum levels of BUN and creatinine in cisplatin-untreated
mice but managed to markedly decrease both BUN and
creatinine in cisplatin-treated animals (Figure 3(a)).
Histological analysis revealed reduced necrosis, vacuoli-
zation, and desquamation of epithelial cells in the renal
tubules of cisplatin +MSC-CM-treated mice when compared
to the animals that received only cisplatin (Figure 3(c)).
Histological score conﬁrmed signiﬁcant reduction of acute
renal injury in cisplatin-treated mice that received MSC-
CM (Figure 3(b)).
As shown in Figures 3(d), 3(e), and 3(f), MSC-CM treat-
ment signiﬁcantly downregulated serum levels of nephrotoxic
and inﬂammatory TNF-α (p < 0 05) and IL-17 (p < 0 05)
and increased serum levels of immunosuppressive IL-10
(p < 0 05), IL-6 (p < 0 05), kynurenine (p < 0 05), and
NO (p < 0 05) in cisplatin-treated mice. Accordingly,
MSC-CM signiﬁcantly downregulated expression of
TNF-α (p < 0 05) and increased expression of IL-6 (p < 0 05)
in the kidneys of cisplatin-treated animals (Figure 3(g)).
3.4. MSC-CM Decreases Inﬂammatory Cell Accumulation in
the Kidneys of Cisplatin-Treated Mice. Application of MSC-
CM did not aﬀect inﬂux of renal-inﬁltrated immune cells in
cisplatin-untreated animals (Figures 3(h) and 4(a), 4(b), and
4(c)). Nevertheless, similar as it was observed after injection
of MSCs, MSC-CMmanaged to signiﬁcantly reduce the pres-
ence ofCD45+ leukocytes (p < 0 05),CD45+CD11b+myeloid
cells (p < 0 01), CD45+F4/80+macrophages (p < 0 01), CD45
+CD11c+DCs (p < 0 01), CD45+CD11b+Ly6G+ neutrophils
(p < 0 01), CD45+CD4+ helper T cells (p < 0 01), and CD45
+CD8+ CTLs (p < 0 01) in the kidneys of cisplatin-injured
mice (Figure 3(g)).
As determined by intracellular staining, in comparison to
cisplatin-only-treated mice, MSC-CM treatment signiﬁ-
cantly increased the total number of immunosuppressive
IL-10-producing DCs (p < 0 01, Figure 4(a), left panel) and
regulatory T cells (p < 0 01, Figure 4(a), right panel) and
attenuated the total number of inﬂammatory TNF-α-pro-
ducing DCs (p < 0 05, Figure 4(b)), IFN-γ- and IL-17-
producing CD8+ cytotoxic T cells (p < 0 01, Figure 4(c)).
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Figure 2: MSCs signiﬁcantly attenuate inﬂux of immune cells and their capacity to produce nephrotoxic and inﬂammatory cytokines. Total
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3.5. The Capacity of MSC-CM to Protect from Cisplatin-
Induced Acute Kidney Injury Is Completely Abrogated by
iNOS Inhibitor. Various mediators are proposed to be
responsible for the immunosuppressive eﬀects of MSCs,
including NO, IDO, TGF-β, HGF, PGE2, and IL-10
[22–24]. IDO plays a key role in immunomodulation
mediated by human MSCs while murine MSCs mainly use
iNOS-dependent suppression of immune response [25].
Accordingly, we investigated the eﬀects of iNOS or IDO
inhibition on MSC-CM-dependent attenuation of cisplatin-
induced nephrotoxicity.
As it is shown in Figure 5, blockade of iNOS by L-NMMA
almost completely diminished the renoprotective eﬀects of
MSC-CM as determined by increased serum levels of BUN
and creatinine (p < 0 05, Figure 5(a)) and histological analy-
sis (Figures 5(b) and 5(c)).
Almost normal morphology with well-preserved brush
border membranes and no loss of tubular epithelial cells
was noticed in cisplatin +MSC-CM-treated animals. On the
contrary, cisplatin +MSC-CM+L-NMMA-treated kidneys
exhibited severe histological changes which included tubular
necrosis and dilation (Figure 5(c)). These ﬁndings were
conﬁrmed by histological scores (Figure 5(b)).
Similar as it was noticed by biochemical and histological
analysis, blockade of iNOS resulted with elevated serum
levels of TNF-α (p < 0 05, Figure 5(d)) and decreased serum
concentration of immunosuppressive IL-10 (p < 0 01,
Figure 5(d)) in the kidneys of cisplatin +MSC-CM+L-
NMMA-treated mice. Signiﬁcantly higher number of inﬂam-
matory TNF-α-producing DCs (p < 0 05, Figure 5(e), left
panel), followed with increased number of IL-17-producing
CTLs (p < 0 05, Figure 5(e), right panel), was noticed in the
kidneys of cisplatin +MSC-CM+L-NMMA-treated mice
when compared to cisplatin +MSC-CM-treated animals
(Figure 4(f)). Interestingly, iNOS inhibition also attenuates
the capacity of MSC-CM to aﬀect inﬂux of regulatory cells
in the injured kidneys. There was signiﬁcantly lower number
of tolerogenic IL-10-producing DCs (p < 0 05, Figure 5(f),
left panel) and IL-10-producing regulatory T cells (p < 0 05,
Figure 5(f), right panel) in the kidneys of cisplatin +MSC-
CM+L-NMMA-treated mice when compared to cisplatin
+MSC-CM-treated animals.
Biochemical and histological analyses indicate that, in
contrast to L-NMMA, IDO inhibitor (1-MT) did not
manage to completely abrogate renoprotective eﬀects of
MSC-CM (Figures 5(a), 5(b), and 5(c)). Signiﬁcant diﬀer-
ence was not observed for serum levels of creatinine and
BUN (Figure 5(a)) and histological scores (Figure 5(b))
between cisplatin +MSC-CM- and cisplatin +MSC-CM
+1-MT-treated animals.
In accordance with results obtained by biochemical
and histological analyses, cellular make-up of cisplatin-
injured kidneys revealed that 1-MT only aﬀected MSC-
CM-mediated suppression of TNF-α production in DCs
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Figure 3: MSCs reduce cisplatin-induced nephrotoxicity via soluble factors. (a) Mice were euthanized 72 h after cisplatin administration, and
blood urea nitrogen (BUN) and plasma creatinine levels are measured. (b) Histological examination was performed with H&E staining.
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(Figure 5(e)) and did not signiﬁcantly alter MSC-CM-
dependent modulation of CTLs and regulatory cells
(Figure 5(f)).
3.6. iNOS Is Important for Activation of IDO in TNF-α-
Stimulated MSCs. Nonstimulated MSCs express both iNOS
and IDO but their expression signiﬁcantly increased after
activation of MSCs by TNF-α (Figure 6(a)). In order to
evaluate the interplay between MSC-derived NO and IDO,
concentration of kynurenine was measured in supernatants
of TNF-α-activated MSCs that were cultured with or with-
out iNOS inhibitor, L-NMMA. As shown in Figure 6(b),
L-NMMA signiﬁcantly attenuated the concentration of
kynurenine in TNF-α-primed MSCs indicating the impor-
tance of iNOS for IDO activity in TNF-α-stimulated MSCs.
4. Discussion
Here, we provide the evidence that intraperitoneal applica-
tion of MSCs and MSC-CM attenuates cisplatin-induced
nephrotoxicity by suppressing inﬁltration and activation of
immune cells in iNOS-dependent manner.
Cisplatin-induced renal injury is followed by increased
release of inﬂammatory TNF-α. As a response to these
inﬂammatory cytokines, endothelial cells in injured kidneys
increase expression of selectins and chemokines which are
involved in leukocyte traﬃcking, resulting with massive
inﬂux of inﬂammatory cells in injured kidneys [26]. MSCs
interact with endothelial cells and, by producing IL-6, down-
regulate expression of adhesion molecules on endothelial
cells, reducing recruitment of leukocytes into the damaged
kidneys [27]. Accordingly, decreased expression of TNF-α
in the kidneys, attenuated serum levels of TNF-α, and
increased expression of IL-6 in renal tissue accompanied with
elevated serum concentration of IL-6, noticed in cisplatin
+MSC-treated mice (Figures 1(d) and 1(g)), were accompa-
nied with reduced inﬁltration of leukocytes in injured
kidneys of these animals (Figure 2(a)).
Among renal-inﬁltrated immune cells, MSC treatment
signiﬁcantly attenuates inﬂux of neutrophils, DCs,
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Figure 5: MSCs attenuate cisplatin-induced acute kidney injury in iNOS-dependent manner. (a) Serum levels of BUN and creatinine. (b)
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macrophages, and CD4+ helper and CD8+ CTLs
(Figure 2(b)) in the kidneys of cisplatin-injured mice.
Neutrophils are reported to inﬁltrate and exacerbate
cisplatin-induced acute kidney injury 24 to 48 h after cis-
platin administration. Although the extent of neutrophil
inﬁltration coincided with the severity of acute kidney injury
and renal dysfunction, their depletion had no impact on the
extent of cisplatin-induced nephrotoxicity [27]. As recently
demonstrated by Tadagavadi et al. [27], cisplatin-mediated
acute kidney injury is not mediated by neutrophils, while
DCs play the most important role in stimulation or suppres-
sion of inﬂammation in cisplatin-induced renal failure. Renal
DCs are immune sentinels with the ability to induce immu-
nity or tolerance in acute kidney injury. IL-10, mainly pro-
duced by renal DCs, attenuates cisplatin nephrotoxicity and
protects from cisplatin-mediated acute kidney injury [28].
Additionally, depletion of IL-10-producing and tolerogenic
renal-inﬁltrated DCs results with aggravation of cisplatin-
induced nephrotoxicity [28, 29].
It is well known that MSCs may suppress maturation
of DCs in IL-10-dependent manner, promoting genera-
tion of their tolerogenic, immunosuppressive phenotype
[30]. In inﬂammatory microenvironment, DCs exposed
to TNF-alpha (produced by inﬂammatory cells) and IL-
10 (produced by MSCs) failed to upregulate maturation
markers [31]. These immature DCs are strongly ham-
pered in their ability to produce TNF-α and to promote
inﬂammation [32].
In line with these observations, downregulated serum
levels of TNF-α and increased serum concentration of IL-
10, noticed in cisplatin +MSC-treated mice (Figure 1(d)),
were accompanied with signiﬁcantly lower number of
renal-inﬁltrated TNF-α-producing DCs (Figure 2(c)).
MSCs are also able to suppress migration of DCs to the
draining lymph nodes and inﬂamed tissues signiﬁcantly
aﬀecting their ability for antigen presentation to CD4+ T
helper (Th) cells and cross-presentation to CD8+ T cells
[33, 34] resulting with attenuated generation and activation
of IFN-γ-producing Th1 and IL-17-producing Th17 cells
and CTLs [35]. Accordingly, we noticed reduced renal
inﬁltration of IFN-γ- and IL-17-producing Th1 and Th17
cells (Figure 2(d)) and CTLs (Figure 2(e)), accompanied
with decreased serum levels of IL-17 (Figure 1(d)) in
cisplatin +MSC-treated mice when compared to cisplatin-
only-treated animals. An important proinﬂammatory role
of IL-17 in the nephrotoxicity induced by cisplatin was
demonstrated by observing protection from cisplatin-
induced functional and histological renal injury in IL-17
and RORγt-deﬁcient mice and in mice treated with anti-
IL-17 antibodies [36].
Homing of MSCs to the sites of renal injury and their
integration and diﬀerentiation into tubular cells were rare
or absent in animal models of acute kidney injury [37].
Accordingly, it is generally considered that MSCs exert their
beneﬁcial eﬀects in paracrine manner, through the produc-
tion of growth factors and cytokines that suppress oxidative
stress, apoptosis, and inﬂammation in damaged kidneys
[22, 23, 25, 38, 39]. In line with these ﬁndings, we showed
here that MSC-CM also attenuates cisplatin-induced
nephrotoxicity (Figure 3) in a similar manner as it was
observed after injection of MSCs (Figure 1).
IDO and NO are important for MSC-mediated suppres-
sion of immune response in acute inﬂammation [25, 40].
IDO promotes the degradation of tryptophan into kynure-
nine and toxic metabolites (quinolinic acid and 3-hydroxy-
anthranillic acid) which suppress proliferation or induce
apoptosis of T cells. NO inhibits phosphorylation of signal
transducer and activator of transcription-5 (Stat5) in T cells,
leading to cell-cycle arrest [22, 23, 25]. Under inﬂammatory
conditions, mouse MSCs increase expression of iNOS [38].
Activation of MSCs by TNF-α resulted with the increased
expression of both iNOS and IDO (Figure 6(a)) whose inter-
play is important for MSC-mediated immunosuppression
[40]. Since, in the presence of inﬂammatory cytokines, NO
increased IDO activity [39], we assume that cisplatin-
induced inﬂammation increased production of TNF-α in
DCs (Figure 2(c)) resulting with increased generation and
activation of IFN-γ-producing CD4+ Th1 cells and CD8+
CTLs (Figures 2(d) and 2(e)) that provoked MSCs to express
iNOS and produce NO. MSC-derived NO increased IDO
activity and MSC-mediated immunosuppression and led to
the attenuation of cisplatin-induced cytotoxicity and inﬂam-
mation (Figure 6(c)). In line with these observations are
increased serum levels of immunosuppressive NO, kynure-
nine (product of IDO activity), and IL-10 (Figures 3(d),
3(e), and 3(f)) accompanied with reduced inﬁltration of
immune cells in the kidneys of cisplatin-treated mice that
received MSC-CM (Figure 3(h)) and attenuated concentra-
tion of kynurenine in supernatants of TNF-α-stimulated
MSCs that were cultured in the presence of iNOS inhibi-
tor, L-NMMA (Figure 6(b)). Blockade of iNOS by L-
NMMA resulted with increased inﬁltration and activation
of inﬂammatory DCs, eﬀector T helper cells, and CTLs,
decreased inﬂux of tolerogenic DCs and regulatory T cells,
and almost completely diminished renoprotective eﬀects of
MSC-CM (Figure 5).
In conclusion, our study provides the evidence that
MSCs, in paracrine, iNOS-dependent manner, attenuate
inﬂammation in cisplatin-induced nephrotoxicity by reduc-
ing inﬂux and the capacity of immune cells, particularly
DCs and T lymphocytes, to produce inﬂammatory cytokines.
These ﬁndings could be helpful in developing new, MSC-
based therapeutic approaches for attenuation of cisplatin-
induced nephrotoxicity.
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